id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-252857-vaq0kwln	Rejdak, Konrad	Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment	2020-04-30		.txt	text/plain	1227	74	47	We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). Hereby we report on the result of a questionaire-based study performed to assess whether adamantanes could exert protective antiviral effect against COVID-19 among different neurological disease patients including multiple sclerosis, parkinsonism and cognitive impairment. In this study, twenty-two patients (10 with multiple sclerosis, 5 with Parkinson's disease and 7 with cognitive impairment) who were tested positive for SARS-CoV-2 and were receiving treatment with either amantadine or memantine on stable registered doses (100mg q.d. and 10mg b.i.d, respectively) for at least 3 months prior to the infection exposure, were surveyed on their laboratory results and clinical status (remote contact with verbally received information).	./cache/cord-252857-vaq0kwln.txt	./txt/cord-252857-vaq0kwln.txt